JOP20170133B1 - عوامل مضادة لمستقبل أنجيوتنسين-1 - Google Patents

عوامل مضادة لمستقبل أنجيوتنسين-1

Info

Publication number
JOP20170133B1
JOP20170133B1 JOP/2017/0133A JOP20170133A JOP20170133B1 JO P20170133 B1 JOP20170133 B1 JO P20170133B1 JO P20170133 A JOP20170133 A JO P20170133A JO P20170133 B1 JOP20170133 B1 JO P20170133B1
Authority
JO
Jordan
Prior art keywords
andnbsp
angiotensin
receptor antagonists
pregnancy
formula
Prior art date
Application number
JOP/2017/0133A
Other languages
English (en)
Inventor
Earl Cable Edward
Stalewski Jacek
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Application granted granted Critical
Publication of JOP20170133B1 publication Critical patent/JOP20170133B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/14—Angiotensins: Related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

يتعلق الاختراع الحالي بالكشف عن مركبات لها الصيغة (I) أو ملح مقبول صيدلانيا منها: AA1-Arg-Val-AA4-AA5-His-Pro-AA8-OH (I), حيث تم تحديد AA1 وAA4 وAA5 وAA8 في المواصفة. ويمكن استخدام مركبات الصيغة (I) لمعالجة ارتفاع ضغط الدم (على سبيل المثال ارتفاع ضغط الدم الناتج عن الحمل)، أو تسمم الحمل، أو مرض كلوي ناتج عن الحمل.
JOP/2017/0133A 2016-06-02 2017-05-29 عوامل مضادة لمستقبل أنجيوتنسين-1 JOP20170133B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662344831P 2016-06-02 2016-06-02
EP16185403 2016-08-23

Publications (1)

Publication Number Publication Date
JOP20170133B1 true JOP20170133B1 (ar) 2022-03-14

Family

ID=58992873

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2017/0133A JOP20170133B1 (ar) 2016-06-02 2017-05-29 عوامل مضادة لمستقبل أنجيوتنسين-1

Country Status (16)

Country Link
EP (1) EP3464324B1 (ar)
JP (1) JP7139251B2 (ar)
BR (1) BR112018074190A2 (ar)
CL (1) CL2018003324A1 (ar)
DK (1) DK3464324T3 (ar)
ES (1) ES2878153T3 (ar)
HU (1) HUE054334T2 (ar)
IL (1) IL262981B2 (ar)
JO (1) JOP20170133B1 (ar)
MX (1) MX2018014364A (ar)
MY (1) MY191062A (ar)
PH (1) PH12018502440A1 (ar)
PL (1) PL3464324T3 (ar)
SI (1) SI3464324T1 (ar)
UA (1) UA123367C2 (ar)
ZA (1) ZA201807767B (ar)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE026131T2 (en) 2008-12-29 2016-05-30 Trevena Inc Beta-arresin effector and preparations and methods for their use

Also Published As

Publication number Publication date
ZA201807767B (en) 2023-04-26
EP3464324A1 (en) 2019-04-10
IL262981B2 (en) 2024-01-01
DK3464324T3 (da) 2021-06-28
IL262981A (en) 2018-12-31
HUE054334T2 (hu) 2021-08-30
JP7139251B2 (ja) 2022-09-20
MY191062A (en) 2022-05-30
JP2019520331A (ja) 2019-07-18
ES2878153T3 (es) 2021-11-18
MX2018014364A (es) 2019-02-14
PH12018502440A1 (en) 2019-09-09
BR112018074190A2 (pt) 2019-03-26
CL2018003324A1 (es) 2019-06-07
SI3464324T1 (sl) 2021-08-31
IL262981B1 (en) 2023-09-01
PL3464324T3 (pl) 2021-10-25
UA123367C2 (uk) 2021-03-24
EP3464324B1 (en) 2021-04-07

Similar Documents

Publication Publication Date Title
PH12018501226A1 (en) Methods for treating huntingtons disease
MY195110A (en) Antibodies to PD-1 and uses Thereof
MY194319A (en) Aldehyde compounds for treating pulmonary fibrosis, hypoxia, and connective tissue and autoimmune disease
EA201891024A1 (ru) Соединения-ингибиторы tank-связывающей киназы
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
EA202092435A2 (ru) Моноклональные антитела против bcma
MA40074A (fr) Composés liant ras multivalents
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
EA201692203A1 (ru) Соединения, ингибирующие tank-связывающую киназу
WO2016044189A8 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists
EA201591420A1 (ru) Гетероарильные соединения и их применение
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
EA201690513A1 (ru) Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний
EA201692525A1 (ru) Замещенные соединения [1,2,4]триазола и имидазола в качестве фунгицидов
EA201591665A1 (ru) Оральные составы деферазирокса
MX2016003823A (es) Inhibidor selectivo de fosfatidil-inositol 3-cinasa-gamma.
MX2017009038A (es) Antagonistas de proteina 1 de interacción con el receptor de nogo que contiene el dominio de inmunoglobulina y repeticiones ricas en leucina (lingo-1) y usos para el tratamiento de trastornos desmielinizantes.
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
EA201692518A3 (ru) Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила
CL2017000074A1 (es) Antagonistas de reproducción de peces
MX2016005473A (es) Metodos y composiciones para mejorar la funcion renal.
PH12018502440A1 (en) Angiotensin-1-receptor antagonists
EA201890444A1 (ru) Способы и составы для снижения выбросов от крупного рогатого скота